Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes

Area of Science:

• Cardiovascular Research
• Metabolic Diseases
• Pharmacology

Background:

• Diabetic cardiomyopathy involves cardiac steatosis and apoptosis, with unclear mechanisms and limited therapies.
• Eplerenone, a mineralocorticoid receptor blocker, shows anti-fibrotic effects in diabetic hearts.
• The impact of eplerenone on fatty-acid accumulation and apoptosis in diabetic hearts requires investigation.

Purpose of the Study:

• To investigate the effects of eplerenone on cardiac steatosis and apoptosis in a rat model of type-II diabetes.
• To elucidate the mechanisms by which eplerenone influences lipid metabolism and cell death in the diabetic heart.

Main Methods:

• Non-hypertensive Zucker Diabetic Fatty (ZDF) rats and Zucker Lean (ZL) rats were used.
• ZDF rats received eplerenone (25 mg/kg) or vehicle for 16 weeks.
• Cardiac structure/function, plasma, and heart tissues were analyzed; in vitro studies used cultured cardiomyocytes exposed to high fatty acids and glucose.

Main Results:

• ZDF rats displayed hyperglycemia, hyperlipidemia, insulin resistance, cardiac steatosis, and diastolic dysfunction.
• Eplerenone treatment reduced cardiac steatosis, mitochondrial oxidation, and apoptosis in ZDF rats, independent of hyperglycemia.
• In vitro, eplerenone ameliorated palmitate-induced fatty-acid uptake, ceramide formation, and apoptosis in cardiomyocytes.

Conclusions:

• Eplerenone attenuates cardiac steatosis and apoptosis in obese/type-II diabetic rats.
• Blocking mineralocorticoid receptors with eplerenone may prevent cardiac remodeling and diastolic dysfunction.
• Eplerenone offers a potential therapeutic strategy for diabetic cardiomyopathy by targeting lipid accumulation and cell death.